Since 2002, AbbVie has blocked numerous biologics, but the nation’s best-selling drug — which has earned $208 billion globally — will have competition in 2023 after two decades of exclusivity.
Four things to know:
1. About six years after its approval, Amgen’s Amjevita will enter the market, and nine more are expected to be ready in 2024, according to the Times.
2. Analysts at Moody’s forecasted Humira’s yearslong monopoly to crumble this year as three biosimilars are poised to premiere this year. In a January report, Moody’s said its sales, which are about $18 billion each year, will fall between 45 percent and 55 percent.
3. OptumRx, UnitedHealth’s pharmacy benefit manager, cleared a spot for the biosimilars on its formulary.
4. Humira’s price has bumped up about 30 times since 2002, and since the end of 2016, its list price has increased 60 percent to over $80,000 per year, according to the Times.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
